Senseonics Holdings' Upcoming Conference Participation
Senseonics Holdings, Inc. (NYSE: SENS) is set to participate in a key healthcare event, showcasing their commitment to revolutionizing diabetes management. This participation is an excellent opportunity for them to highlight their advancements and future plans for continuous glucose monitoring technologies.
Details of the Conference
Conference Format and Schedule
The Stifel 2025 Healthcare Conference will feature a unique format, including a fireside chat and one-on-one meetings with potential investors. The conference is scheduled for a specific date and time, providing a platform for Senseonics to discuss their innovative technologies and business strategies.
Webcast Access Information
For those interested in following the proceedings, the presentation will be accessible through a live and recorded webcast. This can be found in the "Investor Relations" section of their official website, where investors can stay informed about developments concerning the company.
Senseonics and Its Innovative Technology
Senseonics Holdings, Inc. specializes in developing cutting-edge glucose monitoring systems aimed at transforming the lives of individuals managing diabetes. Their flagship products, the Eversense® 365 and Eversense® E3 systems, are designed to offer long-term monitoring solutions through an implantable sensor, enhancing the user experience and ensuring reliable glucose data transmission.
Understanding Continuous Glucose Monitoring
How the Technology Works
The CGM systems developed by Senseonics include a small sensor that is inserted beneath the skin. It communicates with a smart transmitter worn externally, sending glucose readings directly to a mobile application on the user's smartphone. This technology facilitates real-time glucose monitoring, helping users manage their diabetes more effectively.
Benefits of Eversense Technology
The primary advantage of the Eversense systems is their long-term monitoring capabilities. The sensors can remain in place for extended periods, reducing the burden associated with traditional glucose monitoring methods. This innovative approach allows users to maintain better control over their diabetes, leading to improved health outcomes.
Investor Relations and Contact Information
For investors seeking more details or wishing to connect with the company, Jeremy Feffer from LifeSci Advisors serves as the point of contact. Questions and inquiries can be directed to their dedicated email, reinforcing their commitment to maintaining open communication with stakeholders.
Frequently Asked Questions
What is Senseonics Holdings, Inc. known for?
Senseonics is known for developing innovative continuous glucose monitoring systems designed to improve diabetes management.
Where will Senseonics be presenting?
They will participate in the Stifel 2025 Healthcare Conference, engaging with investors and stakeholders.
What are the key features of the Eversense products?
The Eversense systems feature long-term, implantable sensors that transmit data to smartphones for real-time monitoring of glucose levels.
How can one access the conference webcast?
The webcast will be available on the "Investor Relations" section of Senseonics' official website for live and recorded viewing.
Who should investors contact for inquiries about Senseonics?
Investors can contact Jeremy Feffer at LifeSci Advisors for any inquiries regarding the company or its technologies.
